At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 655 enrolled
Drug / intervention
Alogliptin +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of SYR-322 Plus Pioglitazone HCl (Actos®), SYR-322 Alone or Pioglitazone HCl Alone in Subjects With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating Alogliptin, Pioglitazone, and 1 other intervention for Diabetes Mellitus. Completed, enrolled 655 participants across 161 sites in 23 countries.
Detailed Summary
The purpose of this study is to evaluate the combination of alogliptin, once daily (QD), and pioglitazone in patients with type 2 diabetes mellitus who are inadequately controlled with diet and exercise alone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus
CountriesArgentina, Australia, Brazil, Bulgaria, Chile, Croatia, Estonia, Guatemala, Hungary, India, Israel, Latvia, Lithuania, Mexico, New Zealand, Poland, Romania, Russia, Serbia, Slovakia, South Africa, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2006
First PostedNov 2006
Primary CompletionFeb 2008
TodayJul 2026
First PostedNov 3, 2006
Enrollment StartNov 1, 2006
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.7 years ago
Interventions
Alogliptindrug
Alogliptin tablets.
Pioglitazonedrug
Pioglitazone tablets.
Placebodrug
Matching placebo tablets.